Effecty Review: What Its GLP-1 Documentation Establishes—and What It Does Not

01Start with the organization behind the offer

Effecty LLC and its affiliates own and operate the website, according to its terms. Effecty describes itself as a technology platform rather than a medical practice: it does not prescribe medication, and independent licensed providers decide whether treatment is appropriate. The terms identify providers employed by or contracted with Wasef Health P.A. or similar affiliated professional entities. That distinction matters because the website operator, treating clinician and dispensing pharmacy have different responsibilities.

The documented business extends beyond GLP-1 treatment to longevity services and women’s hormone therapy. For weight loss, however, the terms describe a limited-scope medical service and explicitly say these professionals are not acting as patients’ primary care providers. Access through one portal therefore should not be mistaken for comprehensive primary care. Effecty also says it works with board-certified, US-licensed healthcare professionals matched to the patient’s state; those credential claims were not independently verified for this review.

Public documents can establish what a company promises and which entities it names, but not whether every encounter delivers those promises. Our guide to what provider documentation can establish explains that boundary. Here, the materials identify a clinical organization but do not name the dispensing pharmacies or individual treating professionals in advance. Those omissions leave meaningful verification questions for someone deciding whether to enroll.

02Separate the medication menu from the evidence of results

Effecty specifically advertises compounded semaglutide injections and compounded tirzepatide injections for weight loss. Its product pages acknowledge that compounded medications are not FDA approved and are not reviewed by FDA for safety, effectiveness or quality. That disclosure is important, but it does not itself establish either clinical equivalence or inequivalence to approved products. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy.

The distinction is between product evidence and platform evidence. STEP 1 and SURMOUNT-1 studied specific subcutaneous medication regimens, not Effecty’s service or its compounded preparations. Their findings cannot establish Effecty patient outcomes, the quality of an unnamed pharmacy’s preparation or an individual’s likely response. Nor do they support ranking telehealth companies. Our explanation of why a clinical trial is not a company performance report develops this distinction without treating a familiar ingredient name as sufficient proof.

Effecty also lists Mounjaro, Zepbound, Ozempic and Wegovy, along with oral metformin. These listings establish advertised choices, not guaranteed prescriptions. The consulted brand pages do not fully document administration routes or all authorized indications, and the materials do not provide Effecty-specific outcome data. Readers comparing products should keep the evidence questions for approved and compounded medicines separate from the question of whether this particular service is adequately documented.

03Read the price as a billing arrangement

Effecty’s lowest headline prices need their footnotes. Compounded semaglutide starts at $95 for the first month after a $75 discount on a month’s supply; compounded tirzepatide starts at $160 on the same basis. The monthly-plan prices are $170 and $235, respectively. The SAVEMORE promotion advertises up to $300 off, with the plan tables identifying discounts as first-order reductions rather than recurring discounts. A lower monthly equivalent on a longer plan also comes with a different billing interval.

The table preserves those intervals without treating longer plans as month-to-month subscriptions. It does not establish how many shipments each package contains or resolve early-exit rights. Elsewhere, oral metformin is advertised starting at $80 per month, with the same price at every dose, no membership fee and no insurance required. Mounjaro starts at $1,300 per month and Zepbound at $1,400 per month, each conditioned on a three-month starter pack.

Ozempic’s individual page lists a starting price of $1,300 per month, while Wegovy’s lists $1,600. Those figures should not be merged with the compounded-injection schedule. Effecty advertises no membership fee and the same price at every dose on its compounded offering, but its terms still describe a recurring subscription. The practical distinction is that a separate membership charge may be absent while recurring treatment charges remain. The final selected product, promotion and billing period need confirmation together.

04Trace the assessment before assuming access

Effecty’s advertised sequence begins with a medical questionnaire, followed by a chat-based telehealth visit and pharmacy delivery if the patient is eligible. Its terms require participants to be at least 18, be located in a state where the relevant service operates and accept the terms. Enrollment also requires an initial assessment with a doctor or nurse practitioner, with participation dependent on that professional’s clinical judgment. Buying access therefore is not documentation that a prescription will be issued.

The FAQ describes visits through secure patient-portal chat, with a provider response within 24 hours; some states require live video instead. That is more specific than the marketing phrase “24/7 support.” Around-the-clock messaging access does not establish immediate clinical availability. The consulted materials do not identify which states require video, provide complete clinical criteria or specify mandatory testing for every medication. Those are practical details to resolve during enrollment rather than infer from a broad access claim.

Geography is another unresolved point. The FAQ says GLP-1 shipping is available to all US states and also describes nationwide longevity and hormone-therapy shipping. The terms, however, say certain services are available only to people located in certain states. Nationwide shipping does not settle whether a particular consultation, formulation or prescription is available at a patient’s location. A useful confirmation would identify the exact service and medication, not simply repeat that Effecty ships nationwide.

05Identify what payment includes—and what shifts elsewhere

The compounded-plan page says every plan includes supplies, free shipping, a prescription if eligible and ongoing medical support. It also advertises secure messaging and check-ins with the care team. These are useful service commitments, although they do not specify a fixed follow-up schedule or identify the dispensing pharmacy. The terms permit fulfillment at a local pharmacy, but in that arrangement the subscription fee excludes medication and pharmacy fulfillment. That restriction matters when comparing an all-in advertised plan with an outside-pharmacy prescription.

If a prescription moves from a local pharmacy into Effecty’s pharmacy network, the terms say medication and fulfillment costs are added at the beginning of the next billing cycle. Additional medical consultations or laboratory tests may also be requested outside the offered services, and the patient is responsible for completing them. The reviewed documentation does not establish a comprehensive laboratory allowance. An included prescription and continuing support should not be read as a promise that every related service is included.

Effecty says it does not accept insurance, provide superbills or communicate with insurance carriers. Patients may submit receipts themselves, but reimbursement is not guaranteed. The FAQ offers Affirm and Klarna as payment alternatives; Affirm is subject to eligibility and may not be available in all states. These options change payment timing, not the documented clinical offering. Their availability should not be confused with insurance coverage or a promise that financing will be approved.

06Treat delivery claims as several separate promises

The FAQ says a doctor should reach out within 24 hours after purchase. After a prescription is written, it says dispatch can take up to five to seven business days, followed by free expedited two-day shipping. Those are separate stages: contact is not prescribing, and dispatch is not arrival. The FAQ’s additional statement that orders are shipping faster is a company performance claim, not a verified delivery guarantee or a substitute for the stated outer processing window.

The contractual shipping language differs. It describes processing within two to three business days and an average shipping period of four to 12 business days, with possible demand or holiday delays and no weekend or holiday shipping or delivery. It also says shipping charges are calculated at checkout, despite the product page’s free-shipping promise. These descriptions cannot be reconciled confidently from the consulted documentation. A written order-specific explanation would be more useful than assuming the shortest timeline and lowest charge both apply.

The terms also warn that medication will not arrive in child-resistant packaging. The materials do not describe the carrier, cold-chain arrangements or a specific replacement process for a lost delivery. The terms disclaim Effecty’s responsibility for products damaged or lost during shipping and direct claims to the carrier; patients should clarify who will provide or pay for a replacement. Our guide to reading delivery and cold-chain claims explains why transit speed alone does not document temperature control. FDA explicitly advises not using injectable GLP-1 medication that arrives warm or insufficiently refrigerated and contacting the provider or dispensing pharmacy.

07Locate the financial point of no return

The FAQ describes an initial card hold rather than an immediate charge: the hold remains until a prescription is written, and Effecty says no charge occurs if no prescription is issued. Separately, the monthly-program terms say the initial payment is due when the subscription begins and recurring charges occur approximately every 28–30 days until cancellation. Those intervals should not be treated as an exact calendar-month schedule. The relationship between the hold and subscription commencement deserves confirmation before enrollment.

Cancellation has a different boundary from payment authorization. Effecty tells patients to email hello@effecty.com with the subject “Cancel my account” before the prescription is sent to the pharmacy if they want to stop the current order. Once that handoff occurs, only future shipments can be canceled. The terms call paid subscription fees nonrefundable, say prescription sales are final and do not accept prescription returns for reuse or resale. Suspected filling errors should be reported to the same email address.

There is also an “On-demand” option: the terms allow automatic payments to be switched off through the secure account or by email. Additional monthly subscription charges then stop until the patient orders a refill or reactivates automatic payments. That is useful flexibility in the documented monthly program, but it does not resolve how pauses, cancellation or refunds apply to three-, six- or twelve-month plans. A pause should not be assumed to unwind an already-paid longer billing period.

08Ask what follow-up will demonstrate

Effecty documents ongoing support, secure messaging and care-team check-ins, but these promises are not the same as a published monitoring protocol. The materials do not establish a fixed review cadence, complete testing requirements or measured long-term outcomes. A prospective patient can ask who reviews response and tolerability, when that review occurs and how concerns move from customer support to a treating professional. Those questions test the clinical substance of follow-up rather than just whether another shipment can be arranged.

NIDDK describes medication selection as a discussion of benefits, side effects, health conditions, other medicines, family history and costs. Follow-up concerns response and tolerability, and treatment duration depends on those factors. FDA also reports errors in measuring or administering compounded GLP-1 medication, including some associated with hospitalization. Those reports are not an Effecty-specific event rate. Instructions should be clarified with the prescriber or pharmacist, not reconstructed from product marketing or a review.

For Effecty, the strongest next evidence would be operationally specific: pharmacy identity, clear formulation information, a documented follow-up pathway and consistent order terms. The public materials already disclose several responsibilities and limitations, which is useful. They do not establish that every missing detail is absent from actual care. The appropriate conclusion is narrower: important parts of the service cannot be assessed from the consulted documentation alone, so prospective patients need direct answers before making an informed commitment.

Questions & answers

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

1. FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
2. NIDDK: prescription medications for overweight and obesity ↗
3. Wilding et al. (2021): STEP 1 semaglutide trial ↗
4. Jastreboff et al. (2022): SURMOUNT-1 tirzepatide trial ↗
5. Effecty — faq ↗
6. Effecty — weight loss/compounded semaglutide ↗
7. Effecty — official website ↗
8. Effecty — weight loss/metformin ↗
9. Effecty — weight loss/mounjaro ↗
10. Effecty — weight loss/wegovy ↗
11. Effecty — legal/terms of service ↗
12. Effecty — weight loss/ozempic ↗
13. Effecty — weight loss/zepbound ↗
14. Effecty — weight loss/compounded tirzepatide ↗

Continue reading

• What Public GLP-1 Provider Documents Can—and Cannot—Prove
• FDA-Approved Medicines and Compounded Preparations: Separate Evidence Questions
• A Clinical Trial Is Not a Telehealth Company Performance Report
• Reading GLP-1 Cold-Chain and Delivery Claims Carefully
• Follow-up Is a Clinical Question, Not Just a Renewal Notice